Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Antiplatelet Therapy May Protect Renal Function in Some Lupus Patients

Lara C. Pullen, PhD  |  May 29, 2018

However, researchers acknowledge their results do not resolve the controversy over whether antiplatelet agents or anticoagulants are more beneficial for this patient population.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Hanaoka H, Iida H, Kiyokawa T, et al. Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome. PLoS One. 2018 May 3;13(5):e0196172. eCollection 2018.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:antiplatelet therapyestimated glomerular filtration rate (eGFR)Lupus nephritislupus nephritis class IVRenal

Related Articles

    Antiphospholipid Antibody Testing Update

    January 13, 2012

    Successes, challenges, and controversies of diagnostic methods for APS

    APS: What Rheumatologists Should Know about Hughes Syndrome

    February 17, 2016

    The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…

    Why Antiphospholipid Antibody Syndrome Should Be On Your Radar

    February 1, 2014

    With a wide range of clinical manifestations and frequent occurrence among rheumatology patients, APS is one for rheumatologists to watch

    A Young Disease: A Holistic Approach to the Treatment of Antiphospholipid Syndrome

    September 8, 2022

    Although progress has been made in recent years, rheumatologists still have a lot of questions regarding best management practices for antiphospholipid syndrome (APS). During a session of EULAR 2022, Ricard Cervera, MD, PhD, described a holistic approach.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences